CA2692632A1 - Procedes et compositions de traitement du cancer et d'autres maladies associees a l'angiogenese - Google Patents

Procedes et compositions de traitement du cancer et d'autres maladies associees a l'angiogenese Download PDF

Info

Publication number: CA2692632A1
Authority: CA; Canada
Prior art keywords: ang; sirna; nucleic acid; expression; composition
Prior art date: 2007-07-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2692632

Other languages

English (en)

Inventor

Frank Y Xie

Xiaodong Yang

Yijia Liu

Qing Zhou

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Silence Therapeutics PLC

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-06

Filing date

2008-07-03

Publication date

2009-01-15

2008-07-03 Application filed by Individual filed Critical Individual

2009-01-15 Publication of CA2692632A1 publication Critical patent/CA2692632A1/fr

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 52
239000000203 mixture Substances 0.000 title claims description 42
230000033115 angiogenesis Effects 0.000 title claims description 38
206010028980 Neoplasm Diseases 0.000 title claims description 12
201000011510 cancer Diseases 0.000 title claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 24
201000010099 disease Diseases 0.000 title description 23
238000011282 treatment Methods 0.000 title description 9
108020004707 nucleic acids Proteins 0.000 claims abstract description 60
102000039446 nucleic acids Human genes 0.000 claims abstract description 60
150000007523 nucleic acids Chemical class 0.000 claims abstract description 60
101100481410 Mus musculus Tek gene Proteins 0.000 claims abstract description 55
101100481408 Danio rerio tie2 gene Proteins 0.000 claims abstract description 53
230000014509 gene expression Effects 0.000 claims abstract description 52
108020004459 Small interfering RNA Proteins 0.000 claims description 235
239000004055 small Interfering RNA Substances 0.000 claims description 228
108090000623 proteins and genes Proteins 0.000 claims description 61
102000004169 proteins and genes Human genes 0.000 claims description 26
229920001577 copolymer Polymers 0.000 claims description 23
239000002105 nanoparticle Substances 0.000 claims description 16
230000008685 targeting Effects 0.000 claims description 11
239000004472 Lysine Substances 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 8
238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 7
230000009368 gene silencing by RNA Effects 0.000 claims description 7
108010048154 Angiopoietin-1 Proteins 0.000 claims description 5
102000009088 Angiopoietin-1 Human genes 0.000 claims description 5
108010048036 Angiopoietin-2 Proteins 0.000 claims description 5
102000009075 Angiopoietin-2 Human genes 0.000 claims description 5
229940124597 therapeutic agent Drugs 0.000 claims description 4
108060003951 Immunoglobulin Proteins 0.000 claims description 3
102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 3
108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
102000018358 immunoglobulin Human genes 0.000 claims description 3
102000009840 Angiopoietins Human genes 0.000 abstract description 4
108010009906 Angiopoietins Proteins 0.000 abstract description 4
230000019491 signal transduction Effects 0.000 abstract description 3
241000282414 Homo sapiens Species 0.000 description 67
210000004027 cell Anatomy 0.000 description 67
108091081021 Sense strand Proteins 0.000 description 33
230000000692 anti-sense effect Effects 0.000 description 33
238000001890 transfection Methods 0.000 description 33
235000018102 proteins Nutrition 0.000 description 24
210000001519 tissue Anatomy 0.000 description 23
230000005764 inhibitory process Effects 0.000 description 22
230000003247 decreasing effect Effects 0.000 description 17
230000000694 effects Effects 0.000 description 17
230000037361 pathway Effects 0.000 description 17
241000699666 Mus <mouse, genus> Species 0.000 description 16
230000002401 inhibitory effect Effects 0.000 description 15
230000001404 mediated effect Effects 0.000 description 15
238000008157 ELISA kit Methods 0.000 description 13
239000002609 medium Substances 0.000 description 13
239000013642 negative control Substances 0.000 description 13
229920000642 polymer Polymers 0.000 description 12
230000003833 cell viability Effects 0.000 description 11
230000002441 reversible effect Effects 0.000 description 11
239000000243 solution Substances 0.000 description 11
125000000539 amino acid group Chemical group 0.000 description 10
238000003149 assay kit Methods 0.000 description 9
JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 9
239000012895 dilution Substances 0.000 description 8
238000010790 dilution Methods 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
108020004999 messenger RNA Proteins 0.000 description 8
108090000765 processed proteins & peptides Proteins 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 7
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 7
238000010606 normalization Methods 0.000 description 7
241000894007 species Species 0.000 description 7
108091034117 Oligonucleotide Proteins 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
102100022014 Angiopoietin-1 receptor Human genes 0.000 description 5
108060001084 Luciferase Proteins 0.000 description 5
239000005089 Luciferase Substances 0.000 description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
230000037440 gene silencing effect Effects 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
239000003446 ligand Substances 0.000 description 5
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
230000008901 benefit Effects 0.000 description 4
229920006317 cationic polymer Polymers 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000009467 reduction Effects 0.000 description 4
102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
241000699660 Mus musculus Species 0.000 description 3
229920002873 Polyethylenimine Polymers 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000012790 confirmation Methods 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
230000007783 downstream signaling Effects 0.000 description 3
230000030279 gene silencing Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
238000002156 mixing Methods 0.000 description 3
230000014399 negative regulation of angiogenesis Effects 0.000 description 3
230000001613 neoplastic effect Effects 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
238000012216 screening Methods 0.000 description 3
230000003068 static effect Effects 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
201000009030 Carcinoma Diseases 0.000 description 2
101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 2
101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 2
239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
101100434911 Mus musculus Angpt1 gene Proteins 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
108010039918 Polylysine Proteins 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000002491 angiogenic effect Effects 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
230000012010 growth Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 2
231100001083 no cytotoxicity Toxicity 0.000 description 2
229960001972 panitumumab Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920000656 polylysine Polymers 0.000 description 2
230000004853 protein function Effects 0.000 description 2
238000001338 self-assembly Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
210000001685 thyroid gland Anatomy 0.000 description 2
238000003151 transfection method Methods 0.000 description 2
210000003556 vascular endothelial cell Anatomy 0.000 description 2
STGXGJRRAJKJRG-JDJSBBGDSA-N (3r,4r,5r)-5-(hydroxymethyl)-3-methoxyoxolane-2,4-diol Chemical class CO[C@H]1C(O)O[C@H](CO)[C@H]1O STGXGJRRAJKJRG-JDJSBBGDSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
101150040698 ANGPT2 gene Proteins 0.000 description 1
206010060934 Allergic oedema Diseases 0.000 description 1
208000003120 Angiofibroma Diseases 0.000 description 1
102100034608 Angiopoietin-2 Human genes 0.000 description 1
102400000344 Angiotensin-1 Human genes 0.000 description 1
101800000734 Angiotensin-1 Proteins 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
208000017897 Carcinoma of esophagus Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
208000009774 Follicular Cyst Diseases 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
238000011460 HER2-targeted therapy Methods 0.000 description 1
208000002260 Keloid Diseases 0.000 description 1
239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
208000030289 Lymphoproliferative disease Diseases 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
206010027514 Metrorrhagia Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
101100108856 Mus musculus Angpt2 gene Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
208000000592 Nasal Polyps Diseases 0.000 description 1
206010029113 Neovascularisation Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
206010031252 Osteomyelitis Diseases 0.000 description 1
208000008558 Osteophyte Diseases 0.000 description 1
206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
241001111421 Pannus Species 0.000 description 1
208000034038 Pathologic Neovascularization Diseases 0.000 description 1
206010034665 Peritoneal fibrosis Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
108010076289 Platelet-Derived Growth Factor Receptors Proteins 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010037649 Pyogenic granuloma Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
206010038687 Respiratory distress Diseases 0.000 description 1
206010038933 Retinopathy of prematurity Diseases 0.000 description 1
206010061934 Salivary gland cancer Diseases 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
108010090091 TIE-2 Receptor Proteins 0.000 description 1
102000012753 TIE-2 Receptor Human genes 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
208000009443 Vascular Malformations Diseases 0.000 description 1
208000013058 Weber syndrome Diseases 0.000 description 1
238000012084 abdominal surgery Methods 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
206010064930 age-related macular degeneration Diseases 0.000 description 1
239000000556 agonist Substances 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
230000006481 angiogenic pathway Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000003527 anti-angiogenesis Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
229940120638 avastin Drugs 0.000 description 1
229960000397 bevacizumab Drugs 0.000 description 1
230000008238 biochemical pathway Effects 0.000 description 1
230000008236 biological pathway Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
201000001531 bladder carcinoma Diseases 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
201000007293 brain stem infarction Diseases 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
208000006990 cholangiocarcinoma Diseases 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
201000010989 colorectal carcinoma Diseases 0.000 description 1
230000007748 combinatorial effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
229940121647 egfr inhibitor Drugs 0.000 description 1
230000005684 electric field Effects 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
229960001433 erlotinib Drugs 0.000 description 1
201000005619 esophageal carcinoma Diseases 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
201000010934 exostosis Diseases 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
208000010749 gastric carcinoma Diseases 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
230000003779 hair growth Effects 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
201000011066 hemangioma Diseases 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
229940022353 herceptin Drugs 0.000 description 1
238000013537 high throughput screening Methods 0.000 description 1
102000044072 human ANGPT1 Human genes 0.000 description 1
102000047825 human ANGPT2 Human genes 0.000 description 1
102000044214 human TEK Human genes 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
201000001371 inclusion conjunctivitis Diseases 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
210000001117 keloid Anatomy 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000002430 laser surgery Methods 0.000 description 1
238000002647 laser therapy Methods 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
208000002780 macular degeneration Diseases 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000000693 micelle Substances 0.000 description 1
201000003142 neovascular glaucoma Diseases 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
230000035778 pathophysiological process Effects 0.000 description 1
229920002704 polyhistidine Polymers 0.000 description 1
230000001124 posttranscriptional effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
230000004952 protein activity Effects 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
208000002815 pulmonary hypertension Diseases 0.000 description 1
230000005855 radiation Effects 0.000 description 1
102000027426 receptor tyrosine kinases Human genes 0.000 description 1
108091008598 receptor tyrosine kinases Proteins 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
201000003804 salivary gland carcinoma Diseases 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
102000034285 signal transducing proteins Human genes 0.000 description 1
108091006024 signal transducing proteins Proteins 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
206010073373 small intestine adenocarcinoma Diseases 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
201000000498 stomach carcinoma Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229960002812 sunitinib malate Drugs 0.000 description 1
229940034785 sutent Drugs 0.000 description 1
201000004595 synovitis Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940120982 tarceva Drugs 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
206010044325 trachoma Diseases 0.000 description 1
229960000575 trastuzumab Drugs 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
208000010570 urinary bladder carcinoma Diseases 0.000 description 1
230000006444 vascular growth Effects 0.000 description 1
239000013598 vector Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000013603 viral vector Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

CA 2692632 2007-07-06 2008-07-03 Procedes et compositions de traitement du cancer et d'autres maladies associees a l'angiogenese Abandoned CA2692632A1 (fr)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US95851907P	2007-07-06	2007-07-06
US60/958,519		2007-07-06
US96608507P	2007-08-24	2007-08-24
US60/966,085		2007-08-24
US13187608P	2008-06-12	2008-06-12
US61/131,876		2008-06-12
PCT/US2008/008232 WO2009008990A2 (fr)	2007-07-06	2008-07-03	Procédés et compositions de traitement du cancer et d'autres maladies associées à l'angiogenèse

Publications (1)

Publication Number	Publication Date
CA2692632A1 true CA2692632A1 (fr)	2009-01-15

Family

ID=40229333

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2692632 Abandoned CA2692632A1 (fr)	2007-07-06	2008-07-03	Procedes et compositions de traitement du cancer et d'autres maladies associees a l'angiogenese

Country Status (6)

Country	Link
US (1)	US20110015249A1 (fr)
EP (1)	EP2170351A4 (fr)
JP (1)	JP2010532662A (fr)
CN (1)	CN101959521A (fr)
CA (1)	CA2692632A1 (fr)
WO (1)	WO2009008990A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010094491A1 (fr) *	2009-02-18	2010-08-26	Silence Therapeutics Ag	Moyen d'inhibition de l'expression de ang2
US9096643B2 (en) *	2010-08-27	2015-08-04	Milica Radisic	Cell-protective peptides and uses thereof
US20140315973A1 (en) *	2010-10-07	2014-10-23	Agency For Science, Technology And Research	Parp-1 inhibitors
GB201102283D0 (en) *	2011-02-09	2011-03-23	Ucl Business Plc	Treatment
CA3022877A1 (fr) *	2016-02-02	2017-08-10	Olix Pharmaceuticals, Inc.	Traitement de maladies associees a l'angiogenese au moyen de complexes d'arn ciblant angpt2 et pdgfb
EP4035659A1 (fr)	2016-11-29	2022-08-03	PureTech LYT, Inc.	Exosomes destinés à l'administration d'agents thérapeutiques
CN108888756A (zh) *	2018-07-25	2018-11-27	韩曙	C16多肽和血管生成素Ang1的应用和应用二者的药物
WO2025247332A1 (fr) *	2024-05-31	2025-12-04	石药集团中奇制药技术（石家庄）有限公司	Molécule d'acide nucléique à double cible pour inhiber l'expression des gènes vegfa et ang-2

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6506559B1 (en) *	1997-12-23	2003-01-14	Carnegie Institute Of Washington	Genetic inhibition by double-stranded RNA
WO1999042091A2 (fr) *	1998-02-19	1999-08-26	Massachusetts Institute Of Technology	Compositions d'apport dans des cellules
US7163695B2 (en) *	1999-12-29	2007-01-16	Mixson A James	Histidine copolymer and methods for using same
US20050159380A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
US7081443B2 (en) *	2002-05-21	2006-07-25	Korea Advanced Institutes Of Science And Technology (Kaist)	Chimeric comp-ang1 molecule
US20040115640A1 (en) *	2002-12-11	2004-06-17	Isis Pharmaceuticals Inc.	Modulation of angiopoietin-2 expression
CN1720257A (zh) *	2002-08-06	2006-01-11	因特拉迪格姆公司	通过导入干扰rna在体内下调靶基因表达的方法
WO2006006948A2 (fr) *	2002-11-14	2006-01-19	Dharmacon, Inc.	Methodes et compositions permettant de selectionner des arnsi presentant une fonctionnalite amelioree
CA2522730A1 (fr) *	2003-04-18	2004-11-04	The Trustees Of The University Of Pennsylvania	Compositions et methodes d'inhibition par arnic de l'angiopoietine 1 et 2 et de leur recepteur tie2
EP1711172A4 (fr) *	2003-12-23	2008-07-16	Univ Pennsylvania	Compositions et procedes pour la therapie combinee de maladie

2008
- 2008-07-03 CA CA 2692632 patent/CA2692632A1/fr not_active Abandoned
- 2008-07-03 US US12/667,889 patent/US20110015249A1/en not_active Abandoned
- 2008-07-03 CN CN2008800236587A patent/CN101959521A/zh active Pending
- 2008-07-03 WO PCT/US2008/008232 patent/WO2009008990A2/fr not_active Ceased
- 2008-07-03 EP EP08779951A patent/EP2170351A4/fr not_active Withdrawn
- 2008-07-03 JP JP2010514869A patent/JP2010532662A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2010532662A (ja)	2010-10-14
WO2009008990A3 (fr)	2009-06-04
EP2170351A2 (fr)	2010-04-07
WO2009008990A2 (fr)	2009-01-15
US20110015249A1 (en)	2011-01-20
CN101959521A (zh)	2011-01-26
EP2170351A4 (fr)	2011-07-06

Legal Events

Date	Code	Title	Description
2012-07-03	FZDE	Dead

Publication	Publication Date	Title
US20110015249A1 (en)	2011-01-20	Methods and compositions for treatment of cancer and other angiogenesis-related diseases
EP3241840B1 (fr)	2022-07-27	Inhibition de la signalisation axl dans une thérapie antimétastasique
KR101867414B1 (ko)	2018-06-14	호흡기 질환 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 호흡기 질환 예방 또는 치료용 조성물
Kim et al.	2006	Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice
KR20080041145A (ko)	2008-05-09	암 및 다른 신생혈관증식 질환을 치료하기 위한 ＲＮＡｉ치료제의 조성물 및 방법
EP3646887A1 (fr)	2020-05-06	Conjugué de protéine de vegf-grab et de médicament, et son utilisation
WO2009151539A1 (fr)	2009-12-17	Compositions et procédés utilisant des molécules d’arnsi pour le traitement de gliomes
US20090203894A1 (en)	2009-08-13	Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
US20160108378A1 (en)	2016-04-21	Inhibition of AXL Signaling in Anti-Metastatic Therapy
KR20120048613A (ko)	2012-05-15	Ｓｐａｒｃ 안티센스 조성물과 이들의 용도
JP2011500023A (ja)	2011-01-06	インビトロ及びインビボでＶＥＧＦＲ１発現を低減するための治療用ｓｉＲＮＡ分子
CN104189920B (zh)	2017-02-01	逆转肿瘤多药耐药的基因组合物h‑R3/PAMAM G5/MDR1 siRNA及其应用
CN104189919A (zh)	2014-12-10	针对egfr的单克隆抗体修饰的pamam自组装转基因组合物及应用
WO2014035828A2 (fr)	2014-03-06	Inhibition de la signalisation axl dans une thérapie anti-métastasique
CN115919888A (zh)	2023-04-07	一种用于治疗多种肿瘤的核酸干扰药物组合物
HK1127276A (en)	2009-09-25	Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
HK1245806B (en)	2023-03-24	Inhibition of axl signaling in anti-metastatic therapy
US20130209542A1 (en)	2013-08-15	Pharmaceutical carrier and pharmaceutical composition for inhibiting angiogenesis